Two vaccines specifically designed for the COVID-19 variant Omicron are on the verge of approval in the EU, according to information available to Europe.Table. The European Medicines Agency (EMA) is expected to grant clearance for the vaccines from Biontech/Pfizer and Moderna on Thursday. The EU has concluded supply agreements with both manufacturers. Therefore, the adapted vaccine should be available to EU citizens as early as the next few weeks. The EU has concluded contracts with the manufacturer Biontech/Pfizer for the supply of particularly large quantities.
Continue reading now
Get 30 days of free access to the Decision Brief to read these and more quality news every day.
Are you already a guest at the Europe.Table? Log in now